SCHEMBL1270367

SCHEMBL1270367

CNc1ccc(C(N)=O)cc1N

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCI P41743 1/20 0.73
KDM4E B2RXH2 8/20 0.49
ALDH1A1 P00352 7/20 0.49
GAA P10253 7/20 0.49
MAPT P10636 7/20 0.49
HPGD P15428 4/20 0.49
THRB P10828 3/20 0.49
GFER P55789 2/20 0.49
HTT P42858 1/20 0.49
PLEC Q15149 1/20 0.49
GLA P06280 3/20 0.47
HSD17B10 Q99714 4/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
NPC1 O15118 1/20 0.45
RCE1 Q9Y256 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
NNMT P40261 1/20 0.44
APP P05067 1/20 0.44
PRSS1 P07477 4/20 0.43
PTGER4 P35408 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14190740 0.85 PRKCI (0.53) PRKCIKDM4EALDH1A1GAAGLA
SCHEMBL1067119 0.85 PRKCI (0.73) PRKCIKDM4EALDH1A1GAAMAPT
SCHEMBL2245773 0.85 PRKCI (1.00) PRKCIKDM4EALDH1A1GAAMAPT
SCHEMBL2248152 0.83 PRKCI (0.71) PRKCIKDM4EALDH1A1GAAMAPT
SCHEMBL18833886 0.83 PRKCI (0.71) PRKCIKDM4EALDH1A1GAAMAPT
Hydrochloric Acid SCHEMBL18691959 0.83 PRKCI (0.71) PRKCIKDM4EALDH1A1GAAMAPT
SCHEMBL10600114 0.81 PRKCI (0.54) PRKCIKDM4EALDH1A1GAAMAPT
SCHEMBL542066 0.81 PRKCI (0.69) PRKCIKDM4EALDH1A1GAAMAPT
SCHEMBL18229474 0.81 PRKCI (0.69) PRKCIKDM4EALDH1A1GAAMAPT
SCHEMBL27011562 0.81 PRSS1 (0.66) PRKCIPRSS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10975287-B2 Heterocyclic amides useful as protein modulators GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED 2021-04-13 US disclosed
US-10975287-B2 Heterocyclic amides useful as protein modulators GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED 2021-04-13 US disclosed
US-20200325126-A1 HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-10-15 US disclosed
US-20200325126-A1 HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2020-10-15 US disclosed
EP-3440072-B1 HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS GLAXOSMITHKLINE IP DEV LTD (GB) 2020-01-29 EP disclosed
EP-3440072-B1 HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS GLAXOSMITHKLINE IP DEV LTD (GB) 2020-01-29 EP disclosed
CN-109563081-A It can be used as the heterocycleamide class of protein modulators 葛兰素史克知识产权开发有限公司 2019-04-02 CN disclosed
EP-3440072-A1 HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS GlaxoSmithKline Intellectual Property Development Ltd (GB) 2019-02-13 EP disclosed
WO-2017175156-A1 HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2017-10-12 WO disclosed
WO-2017175156-A1 HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2017-10-12 WO disclosed
US-20080153837-A1 Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof AVENTIS PHARMA S.A. (FR) 2008-06-26 US disclosed
US-20080125358-A1 Methods for Chk2 inhibitor patient selection UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL 2008-05-29 US disclosed
US-20080125358-A1 Methods for Chk2 inhibitor patient selection UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL 2008-05-29 US disclosed
US-20070185173-A1 Process for the Preparation of the Salts of 4-(Benzimidazolylmethylamino)-Benzamides BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-08-09 US disclosed
US-20070185333-A1 Process for the Preparation of 4-(Benzimidazolylmethylamino)-Benzamides and the Salts Thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-08-09 US disclosed
WO-2007071742-A1 IMPROVED PROCESS FOR THE PREPARATION OF 4-(BENZIMIDAZOLYLMETHYLAMINO)-BENZAMIDES AND THE SALTS THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-06-28 WO disclosed
WO-2007071743-A1 IMPROVED PROCESS FOR THE PREPARATION OF THE SALTS OF 4-(BENZIMIDAZOLYLMETHYLAMINO)-BENZAMIDES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-06-28 WO disclosed
US-20070149589-A1 Process for the Preparation of 4-(benzimidazolylmethylamino)benzamidines BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-06-28 US disclosed
US-7202368-B2 Process for the preparation of 4-(benzimidazolymethylamino) benzamidines BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-04-10 US disclosed
US-20060004064-A1 Process for the preparation of 4-(benzimidazolymethylamino) benzamidines BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200325126-A1 HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS ARGLU1, G3BP1, G3BP2 PRKCI 1089/4885KDM4E 2147/4885ALDH1A1 3445/4885
US-10975287-B2 Heterocyclic amides useful as protein modulators ARGLU1, G3BP1, G3BP2 PRKCI 1089/4885KDM4E 2147/4885ALDH1A1 3445/4885
US-20070149589-A1 Process for the Preparation of 4-(benzimidazolylmethylamino)benzamidines DDC, PDK2, ACMSD PRKCI 2861/4885KDM4E 1256/4885ALDH1A1 52/4885
US-20070185173-A1 Process for the Preparation of the Salts of 4-(Benzimidazolylmethylamino)-Benzamides DDC, BCKDK, IL4I1 PRKCI 2814/4885KDM4E 1219/4885ALDH1A1 55/4885
US-20070185333-A1 Process for the Preparation of 4-(Benzimidazolylmethylamino)-Benzamides and the Salts Thereof DDC, BCKDK, ODC1 PRKCI 2551/4885KDM4E 963/4885ALDH1A1 40/4885
US-20060004064-A1 Process for the preparation of 4-(benzimidazolymethylamino) benzamidines DDC, PDK2, ACMSD PRKCI 2973/4885KDM4E 852/4885ALDH1A1 68/4885
US-20080125358-A1 Methods for Chk2 inhibitor patient selection CHEK2, CHEK1, TP53 PRKCI 64/4885KDM4E 1930/4885ALDH1A1 3938/4885
US-20080153837-A1 Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof HSP90B1, HSP90AB1, HSP90AA1 PRKCI 830/4885KDM4E 3419/4885ALDH1A1 3050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.